Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Carmen Valcarce"'
Autor:
Roxanne Dutia, Andrea J Kim, Matthew Modes, Robert Rothlein, Jane M Shen, Ye Edward Tian, Jumana Ihbais, Sam F Victory, Carmen Valcarce, Sharon L Wardlaw
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e65317 (2013)
Activation of brain melanocortin-4 receptors (MC4-R) by α-melanocyte-stimulating hormone (MSH) or inhibition by agouti-related protein (AgRP) regulates food intake and energy expenditure and can modulate neuroendocrine responses to changes in energy
Externí odkaz:
https://doaj.org/article/e44e13271cb540bb9dde7b5507c314ba
Autor:
Klara R. Klein, Schafer C. Boeder, Jennifer L. R. Freeman, Imogene Dunn, Chris Dvergsten, Supradeep Madduri, Erin R. Giovannetti, Carmen Valcarce, John B. Buse, Jeremy H. Pettus
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1439-1447
To determine the effect of TTP399, a hepatoselective glucokinase activator, on the risk of ketoacidosis during insulin withdrawal in individuals with type 1 diabetes (T1D).Twenty-three participants with T1D using insulin pump therapy were randomized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18200ce2d774348839de9adf1d6d0838
https://doi.org/10.1111/dom.14697
https://doi.org/10.1111/dom.14697
Autor:
KLARA KLEIN, SCHAFER C. BOEDER, JENNIFER L. FREEMAN, SUPRADEEP MADDURI, ERIN R. GIOVANNETTI, CARMEN VALCARCE, JOHN B. BUSE, JEREMY PETTUS
Publikováno v:
Diabetes. 71
Identification of adjunctive, oral pharmacotherapies to treat T1D has been limited by risk of DKA. TTP399, an oral hepatoselective GKA, significantly improves glycemia in individuals with T1D compared to placebo. This double-blind, randomized, placeb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c39ac8adac7929a292b40adaac541012
https://doi.org/10.2337/db22-835-p
https://doi.org/10.2337/db22-835-p
Autor:
Klara R, Klein, Jennifer L R, Freeman, Imogene, Dunn, Chris, Dvergsten, M Sue, Kirkman, John B, Buse, Carmen, Valcarce, Wendy S, Lane
Publikováno v:
Diabetes Care
OBJECTIVE Despite advances in exogenous insulin therapy, many patients with type 1 diabetes do not achieve acceptable glycemic control and remain at risk for ketosis and insulin-induced hypoglycemia. We conducted a randomized controlled trial to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::059a2c4d835b6e69b6b6eed260812df7
https://doi.org/10.2337/figshare.13635230
https://doi.org/10.2337/figshare.13635230
Publikováno v:
Alzheimer's & Dementia. 16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a251e3aa00b8602d0efcdc4a5a6c9217
https://doi.org/10.1002/alz.041198
https://doi.org/10.1002/alz.041198
Publikováno v:
Diabetes. 69
The Simplici-T1 trial (NCT03335371), designed to explore the safety and efficacy of TTP399 as an oral adjunctive therapy for T1DM, showed that addition of TTP399 to an optimized insulin regimen produced a statistically significant improvement in HbA1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2726a9ec454723c697c124579efc542e
https://doi.org/10.2337/db20-123-lb
https://doi.org/10.2337/db20-123-lb
Publikováno v:
Diabetes. 69
Identification of adjunctive, oral pharmacotherapies to treat type 1 diabetes (T1D) has been limited by hypoglycemia and ketoacidosis. TTP399 is a liver-selective oral glucokinase activator. In type 2 diabetes (n=190), TTP399 was shown to reduce A1C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef31edb9e8d2cee1e4ffcfe1ff567612
https://doi.org/10.2337/db20-122-lb
https://doi.org/10.2337/db20-122-lb
Publikováno v:
Diabetes. 68
TTP273, an oral, non-peptide GLP-1R agonist showed significant placebo-subtracted reductions in A1c of 0.9 and 0.7% when dosed at 150mg QPM or BID, respectively, in LOGRA, a 12-week, phase 2, double-blind, placebo-controlled randomized study [Diabete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::416b794bb8f50702579eadda7803e506
https://doi.org/10.2337/db19-1015-p
https://doi.org/10.2337/db19-1015-p
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator
Autor:
Carmen Valcarce, Kit Keller, Imogene Dunn, John B. Buse, Adrian Vella, Jennifer L. R. Freeman
The therapeutic success of interventions targeting glucokinase (GK) activation for the treatment of type 2 diabetes has been limited by hypoglycemia, steatohepatitis, and loss of efficacy over time. The clinical characteristics of patients with GK-ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf3661da4abcd2d7cc35102ff336a2b8
Autor:
Carmen Valcarce, Mark S. Kindy, Matthew J. Kostura, Aaron H. Burstein, Dharma Rao Polisetti, Adnan M. M. Mjalli, Robert K. Andrews
Publikováno v:
Alzheimer's & Dementia. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::492f2061e36705fc93c60ceec8570131
https://doi.org/10.1016/j.jalz.2014.05.1119
https://doi.org/10.1016/j.jalz.2014.05.1119